LT3105328T - Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr - Google Patents

Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr

Info

Publication number
LT3105328T
LT3105328T LTEP15749644.9T LT15749644T LT3105328T LT 3105328 T LT3105328 T LT 3105328T LT 15749644 T LT15749644 T LT 15749644T LT 3105328 T LT3105328 T LT 3105328T
Authority
LT
Lithuania
Prior art keywords
construction containing
containing crispr
genome construction
component genome
component
Prior art date
Application number
LTEP15749644.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Ryan Gill
Andrew GARST
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53800598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3105328(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of LT3105328T publication Critical patent/LT3105328T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
LTEP15749644.9T 2014-02-11 2015-02-11 Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr LT3105328T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938608P 2014-02-11 2014-02-11
PCT/US2015/015476 WO2015123339A1 (en) 2014-02-11 2015-02-11 Crispr enabled multiplexed genome engineering

Publications (1)

Publication Number Publication Date
LT3105328T true LT3105328T (lt) 2020-07-10

Family

ID=53800598

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15749644.9T LT3105328T (lt) 2014-02-11 2015-02-11 Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr

Country Status (23)

Country Link
US (16) US10266849B2 (enExample)
EP (4) EP4063503A1 (enExample)
JP (3) JP2017505145A (enExample)
KR (4) KR102209636B1 (enExample)
CN (2) CN111705365B (enExample)
AU (2) AU2015217208B2 (enExample)
CA (3) CA3161903C (enExample)
CY (1) CY1123115T1 (enExample)
DE (1) DE212015000061U1 (enExample)
DK (1) DK3105328T3 (enExample)
ES (2) ES2974229T3 (enExample)
GB (1) GB2544382B (enExample)
HR (1) HRP20201040T1 (enExample)
HU (2) HUE049634T2 (enExample)
IL (2) IL246951B (enExample)
LT (1) LT3105328T (enExample)
MX (1) MX375420B (enExample)
PL (1) PL3105328T3 (enExample)
PT (1) PT3105328T (enExample)
RS (1) RS60492B1 (enExample)
SI (1) SI3105328T1 (enExample)
SM (1) SMT202000357T1 (enExample)
WO (1) WO2015123339A1 (enExample)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
LT3105328T (lt) 2014-02-11 2020-07-10 The Regents Of The University Of Colorado, A Body Corporate Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
BR122023023211A2 (pt) 2014-04-28 2024-01-23 Recombinetics, Inc. Método de fazer edições de genes multiplex em uma célula de vertebrado ou de embrião primário não-humano
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3957731A1 (en) * 2015-07-15 2022-02-23 Rutgers, The State University of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
US11371040B2 (en) 2015-10-22 2022-06-28 Institut National De La Sante Et De La Recherche Medical (Inserm) Endonuclease-barcoding
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
JP6821598B2 (ja) 2015-12-07 2021-01-27 ザイマージェン インコーポレイテッド Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｌｕｔａｍｉｃｕｍ由来のプロモーター
US11345931B2 (en) 2015-12-14 2022-05-31 President And Fellows Of Harvard College Cas discrimination using tuned guide RNA
WO2017122096A1 (en) * 2016-01-15 2017-07-20 Astrazeneca Ab Gene modification assays
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017214615A1 (en) * 2016-06-10 2017-12-14 President And Fellows Of Harvard College Library-scale engineering of metabolic pathways
CN109312386B (zh) * 2016-06-15 2022-10-25 株式会社图尔金 使用中靶靶标和脱靶靶标的多重靶标系统筛选靶特异性核酸酶的方法及其用途
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
CN109688820B (zh) 2016-06-24 2023-01-10 科罗拉多州立大学董事会（法人团体） 用于生成条形码化组合文库的方法
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3565608A4 (en) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
EP3568470B1 (en) * 2017-01-10 2022-07-06 Christiana Care Health Services, Inc. Methods for in vitro site-directed mutagenesis using gene editing technologies
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
JP7422069B2 (ja) 2017-09-19 2024-01-25 トロピック バイオサイエンシーズ ユーケー リミテッド 真核細胞において遺伝子発現をサイレンシングするための非コードｒｎａ分子の特異性の改変
US10435713B2 (en) 2017-09-30 2019-10-08 Inscripta, Inc. Flow through electroporation instrumentation
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
TWI878212B (zh) 2017-12-05 2025-04-01 瑞典商伊梅爾迪卡製藥公司 用於治療精胺酸酶1缺乏症之方法及組合物
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US10443031B1 (en) 2018-03-29 2019-10-15 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217837A1 (en) 2018-05-11 2019-11-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
CA3108892A1 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3874051A1 (en) * 2018-10-31 2021-09-08 Novozymes A/S Genome editing by guided endonuclease and single-stranded oligonucleotide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
EP3967703B1 (en) * 2019-06-11 2023-07-26 FUJIFILM Corporation Cyclic peptide, cell scaffold material, cell separation material and culture medium
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
CN114245745A (zh) 2019-06-20 2022-03-25 纪念斯隆-凯特琳癌症中心 靶向pik3ca突变的t细胞受体及其用途
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
WO2021007080A1 (en) * 2019-07-08 2021-01-14 Inscripta, Inc. Increased nucleic acid-guided cell editing via a lexa-rad51 fusion protein
BR112022003633A2 (pt) 2019-08-30 2022-06-07 Aeglea Biotherapeutics Inc Métodos para produção de arginase 1 recombinante humana e usos da mesma
JP7689949B2 (ja) 2019-10-03 2025-06-09 アーティサン ディベロップメント ラブズ インコーポレイテッド 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
AU2020402526B2 (en) * 2019-12-10 2025-01-23 Inscripta, Inc. Novel MAD nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
WO2021126886A1 (en) 2019-12-18 2021-06-24 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
CN115135370A (zh) 2020-01-27 2022-09-30 因思科瑞普特公司 电穿孔模块和仪器
JP7791096B2 (ja) 2020-03-10 2025-12-23 セラレス コーポレーション 細胞処理のためのシステム、デバイス、及び方法
KR102772570B1 (ko) 2020-04-02 2025-02-27 중앙대학교 산학협력단 CRISPR/Cas9 시스템을 기반으로 한 유전체 편집 방법 및 이의 용도
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US20240216823A1 (en) 2020-04-28 2024-07-04 Diamant Toys Ltd Gaming kits and methods of playing with housings reconfigurable by retrievable unlocking elements
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
KR102687692B1 (ko) * 2020-07-08 2024-07-24 경상국립대학교산학협력단 미세상동성 기반 말단 결합을 통한 유전자 교정에 이용되는 공여자 핵산 및 이의 용도
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11566241B2 (en) * 2020-10-02 2023-01-31 Inscripta, Inc. Methods and systems for modeling of design representation in a library of editing cassettes
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
WO2022103699A1 (en) * 2020-11-10 2022-05-19 Inscripta, Inc. Transcriptional roadblocks for gene editing and methods of using the same
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
AU2022227650A1 (en) 2021-02-25 2023-10-12 Celyntra Therapeutics Sa Compositions and methods for targeting, editing, or modifying genes
CA3212642A1 (en) * 2021-03-05 2022-09-09 The Board Of Trustees Of The Leland Stanford Junior University In vivo dna assembly and analysis
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CA3223311A1 (en) 2021-06-18 2022-12-22 Andrea BARGHETTI Compositions and methods for targeting, editing or modifying human genes
WO2022267843A1 (en) * 2021-06-21 2022-12-29 Westlake University Library construction method based on long overhang sequence ligation
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
US20240425834A1 (en) 2021-08-24 2024-12-26 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced cellobiohydrolase i production in s. cerevisiae
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4486881A1 (en) 2022-03-01 2025-01-08 Celyntra Therapeutics SA Composition and methods for transgene insertion
JP2025512313A (ja) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
US20250263692A1 (en) 2022-04-12 2025-08-21 Inscripta, Inc. Curing for iterative nucleic acid-guided nuclease editing
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
EP4526884A2 (en) 2022-05-20 2025-03-26 Artisan Development Labs, Inc. Systems and methods for assessing risk of genome editing events
EP4562142A1 (en) 2022-07-27 2025-06-04 Inscripta, Inc. Modulating cellular repair mechanisms for genomic editing
EP4573114A4 (en) 2022-08-19 2026-07-29 Memorial Sloan Kettering Cancer Center T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4683997A2 (en) 2023-03-21 2026-01-28 Cellares Corporation Systems, devices, and methods for electroporation within a cell processing system
US12399193B2 (en) 2023-05-05 2025-08-26 Cellares Corporation Systems, devices, and methods for combined cell processes
EP4735577A2 (en) 2023-06-30 2026-05-06 Cellares Corporation Systems, devices, and methods for fluid transfer within an automated cell processing system
WO2025021702A1 (en) 2023-07-21 2025-01-30 Alia Therapeutics S.R.L. Cas9 orthologue nuclease and uses thereof
EP4766808A1 (en) 2023-08-21 2026-07-01 Cellares Corporation BIOREACTORS AND THEIR PROCESSES OF USE IN AUTOMATIC CELL PROCESSING SYSTEMS
EP4766812A1 (en) 2023-08-21 2026-07-01 Cellares Corporation FLUID REGULATION SYSTEMS, DEVICES AND METHODS IN A CELL PROCESSING SYSTEM
US12337321B2 (en) 2023-08-21 2025-06-24 Cellares Corporation Systems, devices, and methods for automatic cell sorting
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
US12492368B2 (en) 2024-03-11 2025-12-09 Cellares Corporation Monitoring air pressure within a cell processing system
WO2025202944A2 (en) 2024-03-27 2025-10-02 Cellares Corporation Liquid level and flow rate detection within a cell processing system
USD1109621S1 (en) 2024-04-15 2026-01-20 Cellares Corporation Analytical platform for biological material testing

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1028757A (en) 1910-07-28 1912-06-04 Charles Margerison Combined curtain-pole and shade-support.
US1024016A (en) 1910-10-29 1912-04-23 Emma R Bowne Gas-burner.
US1001776A (en) 1911-01-12 1911-08-29 Augustin Scohy Railroad switch and frog.
US1001184A (en) 1911-04-20 1911-08-22 Charles M Coover Non-slipping device.
US1026684A (en) 1911-09-16 1912-05-21 Emil A Lauer Lamp.
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
EP1276861A2 (en) * 2000-03-24 2003-01-22 Maxygen, Inc. Methods for modulating cellular and organismal phenotypes
US20030044866A1 (en) 2001-08-15 2003-03-06 Charles Boone Yeast arrays, methods of making such arrays, and methods of analyzing such arrays
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
MXPA04012614A (es) 2002-06-14 2005-12-14 Diversa Corp Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
JP4447977B2 (ja) 2004-06-30 2010-04-07 富士通マイクロエレクトロニクス株式会社 セキュアプロセッサ、およびセキュアプロセッサ用プログラム。
EP2325332B1 (en) 2005-08-26 2012-10-31 DuPont Nutrition Biosciences ApS Use of CRISPR associated genes (CAS)
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
JP2009521936A (ja) * 2006-01-03 2009-06-11 マサチューセッツ・インスティチュート・オブ・テクノロジー プロモータ工学及び遺伝子制御
PL2034848T3 (pl) 2006-06-16 2017-08-31 Dupont Nutrition Bioscences Aps Bakteria Streptococcus thermophilus
WO2008052101A2 (en) 2006-10-25 2008-05-02 President And Fellows Of Harvard College Multiplex automated genome engineering
WO2009032185A2 (en) 2007-08-28 2009-03-12 The Johns Hopkins University Functional assay for indentification of loss-of-function mutations in genes
US20140121118A1 (en) 2010-11-23 2014-05-01 Opx Biotechnologies, Inc. Methods, systems and compositions regarding multiplex construction protein amino-acid substitutions and identification of sequence-activity relationships, to provide gene replacement such as with tagged mutant genes, such as via efficient homologous recombination
WO2012142591A2 (en) 2011-04-14 2012-10-18 The Regents Of The University Of Colorado Compositions, methods and uses for multiplex protein sequence activity relationship mapping
CA2834375C (en) * 2011-04-27 2020-07-14 Amyris, Inc. Methods for genomic modification
CN104080462B (zh) 2011-12-16 2019-08-09 塔尔盖特基因生物技术有限公司 用于修饰预定的靶核酸序列的组合物和方法
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
CA2897390A1 (en) 2013-01-10 2014-07-17 Ge Healthcare Dharmacon, Inc. Templates, libraries, kits and methods for generating molecules
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
KR20260047646A (ko) 2013-07-09 2026-04-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 멀티플렉스 rna-가이드된 게놈 조작
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
WO2015017866A1 (en) 2013-08-02 2015-02-05 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
EP4074330A1 (en) 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
ES2681622T3 (es) 2013-09-18 2018-09-14 Kymab Limited Métodos, células y organismos
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
WO2015069682A2 (en) 2013-11-05 2015-05-14 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
US20160264995A1 (en) 2013-11-06 2016-09-15 Hiroshima University Vector for Nucleic Acid Insertion
US11326209B2 (en) 2013-11-07 2022-05-10 Massachusetts Institute Of Technology Cell-based genomic recorded accumulative memory
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
KR20160097338A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
LT3105328T (lt) 2014-02-11 2020-07-10 The Regents Of The University Of Colorado, A Body Corporate Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr
JP6416939B2 (ja) 2014-02-13 2018-10-31 タカラ バイオ ユーエスエー，インコーポレイティド 核酸の初期収集物から標的分子を減損させる方法、並びにそれを実施するための組成物及びキット
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
JP2017514488A (ja) 2014-05-02 2017-06-08 タフツ ユニバーシティー 自然コンピテント細胞の形質転換のための方法および装置
WO2015179540A1 (en) 2014-05-20 2015-11-26 Regents Of The University Of Minnesota Method for editing a genetic sequence
WO2015183026A1 (ko) 2014-05-28 2015-12-03 주식회사 툴젠 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2015195798A1 (en) 2014-06-17 2015-12-23 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
GB201411344D0 (en) 2014-06-26 2014-08-13 Univ Leicester Cloning
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
US20160053304A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Depleting Target Sequences Using CRISPR
US20160053272A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Modifying A Sequence Using CRISPR
US20160076093A1 (en) 2014-08-04 2016-03-17 University Of Washington Multiplex homology-directed repair
WO2016021973A1 (ko) 2014-08-06 2016-02-11 주식회사 툴젠 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
WO2016040594A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California Reconstruction of ancestral cells by enzymatic recording
CN113930455A (zh) 2014-10-09 2022-01-14 生命技术公司 Crispr寡核苷酸和基因剪辑
TWI716367B (zh) 2014-10-31 2021-01-21 麻省理工學院 用於常間回文重複序列叢集（ｃｒｉｓｐｒ）之大量平行組合性基因學
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
ES2865268T3 (es) 2014-12-17 2021-10-15 Dupont Us Holding Llc Composiciones y métodos para la edición eficaz de genes en E. coli utilizando sistemas de ARN guía/endonucleasa CAS en combinación con moldes de modificación de polinucleótido circulares
AU2015364286B2 (en) 2014-12-20 2021-11-04 Arc Bio, Llc Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
MX2017014560A (es) 2015-05-15 2018-03-01 Pioneer Hi Bred Int Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia.
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3929287A3 (en) 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
JP2018519811A (ja) 2015-06-29 2018-07-26 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用
WO2017015015A1 (en) 2015-07-17 2017-01-26 Emory University Crispr-associated protein from francisella and uses related thereto
US20180208945A1 (en) 2015-07-28 2018-07-26 Danisco Us Inc. Genome editing systems and methods of use
US11339408B2 (en) 2015-08-20 2022-05-24 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
US10369232B2 (en) 2015-09-21 2019-08-06 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
US20180258411A1 (en) 2015-09-25 2018-09-13 Tarveda Therapeutics, Inc. Compositions and methods for genome editing
US11371040B2 (en) 2015-10-22 2022-06-28 Institut National De La Sante Et De La Recherche Medical (Inserm) Endonuclease-barcoding
EP3350327B1 (en) 2015-10-23 2018-09-26 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
CN106893739A (zh) 2015-11-17 2017-06-27 香港中文大学 用于靶向基因操作的新方法和系统
WO2017089767A1 (en) 2015-11-26 2017-06-01 Dnae Group Holdings Limited Single molecule controls
AU2016365720B2 (en) 2015-12-07 2020-11-26 Arc Bio, Llc Methods and compositions for the making and using of guide nucleic acids
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
CA3007840C (en) 2015-12-07 2020-09-15 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
JP2019500036A (ja) 2015-12-24 2019-01-10 ブレイン・バイオテクノロジー・リサーチ・アンド・インフォメーション・ネットワーク・アクチェンゲゼルシャフトＢＲＡＩＮ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ ａｎｄ Ｉｎｆｏｒｍａｔｉｏｎ Ｎｅｔｗｏｒｋ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 原核生物におけるｄｎａ末端修復経路の再構築
CN109688820B (zh) 2016-06-24 2023-01-10 科罗拉多州立大学董事会（法人团体） 用于生成条形码化组合文库的方法
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases

Also Published As

Publication number Publication date
SI3105328T1 (sl) 2020-09-30
CN111705365A (zh) 2020-09-25
US20200157574A1 (en) 2020-05-21
US10351877B2 (en) 2019-07-16
GB201615434D0 (en) 2016-10-26
EP3105328A4 (en) 2017-07-26
IL261664A (en) 2018-10-31
US10465207B2 (en) 2019-11-05
MX375420B (es) 2025-03-06
US20210254104A1 (en) 2021-08-19
CA3161903C (en) 2025-09-09
US20220119844A1 (en) 2022-04-21
US20190376087A1 (en) 2019-12-12
SMT202000357T1 (it) 2020-09-10
US20180371499A1 (en) 2018-12-27
US20190194693A1 (en) 2019-06-27
US11078498B2 (en) 2021-08-03
DE212015000061U1 (de) 2017-10-12
WO2015123339A1 (en) 2015-08-20
GB2544382A (en) 2017-05-17
KR102496984B1 (ko) 2023-02-06
HUE049634T2 (hu) 2020-09-28
EP4063503A1 (en) 2022-09-28
EP3690044A1 (en) 2020-08-05
PT3105328T (pt) 2020-07-06
CA2938456A1 (en) 2015-08-20
JP2019205478A (ja) 2019-12-05
CA3075047A1 (en) 2015-08-20
JP6863620B2 (ja) 2021-04-21
KR20250006998A (ko) 2025-01-13
EP3985114A1 (en) 2022-04-20
JP2021087454A (ja) 2021-06-10
KR102209636B1 (ko) 2021-01-29
CA2938456C (en) 2022-06-21
US11639511B2 (en) 2023-05-02
US10435715B2 (en) 2019-10-08
US10669559B2 (en) 2020-06-02
NZ723531A (en) 2022-03-25
US10240167B2 (en) 2019-03-26
US10364442B2 (en) 2019-07-30
JP2017505145A (ja) 2017-02-16
US11795479B2 (en) 2023-10-24
US20170240922A1 (en) 2017-08-24
CA3075047C (en) 2022-02-01
AU2018271257A1 (en) 2018-12-13
CN106164271A (zh) 2016-11-23
US10731180B2 (en) 2020-08-04
KR20160122197A (ko) 2016-10-21
EP3105328A1 (en) 2016-12-21
RS60492B1 (sr) 2020-08-31
IL261664B (en) 2020-11-30
AU2018271257B2 (en) 2020-08-13
IL246951B (en) 2019-03-31
US10711284B2 (en) 2020-07-14
US20240093241A1 (en) 2024-03-21
EP3690044C0 (en) 2024-01-10
PL3105328T3 (pl) 2020-10-19
US20170321226A1 (en) 2017-11-09
ES2974229T3 (es) 2024-06-26
CY1123115T1 (el) 2021-10-29
US20200157575A1 (en) 2020-05-21
KR20220142547A (ko) 2022-10-21
AU2015217208B2 (en) 2018-08-30
DK3105328T3 (da) 2020-07-13
US20220364121A1 (en) 2022-11-17
EP3690044B1 (en) 2024-01-10
CN106164271B (zh) 2020-06-02
KR20210002759A (ko) 2021-01-08
GB2544382B (en) 2018-05-30
MX2016010285A (es) 2017-01-11
HRP20201040T1 (hr) 2021-01-08
US20180230493A1 (en) 2018-08-16
US11345933B2 (en) 2022-05-31
CN111705365B (zh) 2024-12-17
US20190390227A1 (en) 2019-12-26
US11702677B2 (en) 2023-07-18
HUE066611T2 (hu) 2024-08-28
US10266849B2 (en) 2019-04-23
US20180230492A1 (en) 2018-08-16
CA3161903A1 (en) 2015-08-20
AU2015217208A1 (en) 2016-09-08
EP3105328B1 (en) 2020-04-08
US9982278B2 (en) 2018-05-29
JP7232540B2 (ja) 2023-03-03
ES2802984T3 (es) 2021-01-22
US20200392539A1 (en) 2020-12-17
US20190264231A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
IL261664B (en) Crispr enabled multiplexed genome engineering
KR102417915B9 (ko) 뉴클레아제 없는 게놈 편집
PL3102722T3 (pl) Frakcjonowanie genomu
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
PL3118311T3 (pl) Antysensowny kwas nukleinowy
DK3140314T3 (da) Kaloriefrit sødestof
DK3188836T3 (da) Dna-syntese
LT3494962T (lt) Skysta inhaliavimo kompozicija, apimanti rpl554
DK3209323T3 (da) Forbedret koaguleringssammensætning
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
IL252591A0 (en) Genomic architecture mapping
EP3374278A4 (en) Collapsible container
FI20155107A (fi) Näyteastia
CL2014002647S1 (es) Contenedor.
CL2014002057S1 (es) Envase
CL2014002058S1 (es) Envase
PL3386877T3 (pl) Pojemnik
CL2014002059S1 (es) Envase
CL2014002056S1 (es) Envase
LT3110812T (lt) Anti-amiloidų junginiai, turintys benzofurazano
CL2015003785S1 (es) Envase.
CL2016000654S1 (es) Envase
CL2016000399S1 (es) Contenedor
CL2015003578S1 (es) Envase
ES1145559Y (es) Envase